483
Halo Pharmaceutical, Inc. d/b/a Cambrex WhippanyFDA 483 - Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany - February 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex in Whippany, NJ, from February 7-17, 2023, identified a significant issue with equipment qualification. The firm was cited for using production equipment in commercial manufacturing that was not appropriately qualified for its intended use. This indicates a critical lapse in ensuring manufacturing equipment meets regulatory standards.
- Inspection Date
- February 17, 2023
- Product Type
- Drugs
Open in Dashboard
ID · 85c16a13-185e-4160-8506-5e5d9a880e64